MILPITAS Calif. Oct. 13 2016 PRNewswire Protagonist Therapeutics Inc. NASDAQ PTGX today announced that the company will present two posters detailing clinical data from a Phase 1 clinical trial of PTG100 and preclinical pharmacokineticspharmacodynamics da...
↧